CoChat

Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again

Long, Adrienne H., Morgenstern, Daniel A., Leruste, Amaury, Bourdeaut, Franck, Davis, Kara L. · 2022 · American Society of Clinical Oncology Educational Book

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

Abstract

The role of immune checkpoint inhibitors (ICIs) in the treatment of pediatric cancers continues to evolve. Such therapies function by augmenting existing antitumor T-cell responses that have been rendered ineffective by inhibitory pathways. Although ICIs have proven highly effective for adult cancers, initial phase I/II clinical trials using single-agent ICIs against unselected pediatric cancers have been overall disappointing. With the exception of pediatric classic Hodgkin lymphoma, responses to ICIs have been infrequent, likely stemming from an inherent difference in the immunogenicity of childhood cancers, which, on average, have far fewer neoantigens than adult cancers. Recently, however, hope has reemerged that certain subsets of children with cancer may benefit from ICI therapies. In preliminary studies, patients with both pediatric hypermutated and SMARCB1-deficient cancers have had impressive responses to ICI therapies, likely as a result of underlying biologies that enhance neoantigen expression and tumoral inflammation. Dedicated trials are ongoing to fully evaluate the efficacy of ICIs for patients with these subsets of pediatric cancer.

Overview

Integrity signals

Registry

Crossref · 10.1200/edbk_349799

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 3

  1. Loeb DM, Cancer Immunol Immunother.
  2. Morgenstern DA, 2021, J Clin Orthod., 39, 15
  3. Chung HC, 2018, J Clin Oncol., 36, 15

Cited by

See all 55

Metadata

Authors
Long, A. H., Morgenstern, D. A., Leruste, A., Bourdeaut, F., & Davis, K. L.
Affiliations
  • Stanford Medicine (US)
  • University of Toronto (CA)
  • Université Paris Sciences et Lettres (FR)
  • Institut Curie (FR)
Venue
American Society of Clinical Oncology Educational Book
Published
2022-07
Volume
42
Issue
42
Pages
781-794
ISSN
  • 1548-8748 (ISSN-L)
  • 1548-8756
OpenAlex
W4280529326
Cited by
53
References
90
Citations by year
2026: 6 · 2025: 18 · 2024: 18 · 2023: 8 · 2022: 3
FWCI
4.94
Type
journal article
Language
en
Open access
closed
Locations
  • American Society of Clinical Oncology Educational Book (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
immune checkpoint inhibitors, childhood cancer, pediatric Hodgkin lymphoma, neoantigens, tumor immunogenicity, antitumor T-cell responses, immunotherapy
MeSH terms
Immune Checkpoint Inhibitors, Child, Hodgkin Disease, Humans, Immunologic Factors, Immunotherapy, Pediatrics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.